Newsroom | 59834 results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib met its primary endpoint of non-inferiority compared to Ocrevus® (ocrelizumab) in reducing disability progression in patients with primary progressive multiple sclerosis (PPMS). Fenebrutinib showed a 12% reduction in the risk of...

BELLINGHAM, Wash.--(BUSINESS WIRE)--The AR Alliance, a division of SPIE focused on augmented reality (AR), proudly announces the addition of AlphaLum, Appotronics, Augmenteum, CREAL, EyeJets, GIS, Gixel, Goertek, Kyocera SLD Laser, Nichia America Corporation, OORYM Optics, OQmented, RAONTECH, Solnil, TDK, TechnoTeam, TriLite Technologies, and University of Rochester to its membership. Members of the AR Alliance reflect the global diversity and strength of the AR hardware development ecosystem,...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Covenant Capital Group (“Covenant”), a leading value-add multifamily real estate investment firm, today announced the final close of Covenant Apartment Fund XII, L.P. (“Fund XII”) with $860.35 million in capital commitments—the largest fundraise in the firm’s 25-year history. In addition, Covenant created a sidecar vehicle for Fund XII, the Covenant Affordable Housing Fund, with $269.73 million in committed capital. The combined capital raised by Covenant for...

PROVO, Utah--(BUSINESS WIRE)--Nu Skin Enterprises Inc. (NYSE: NUS) today announced the relaunch of “The Aging Myth: Unlocking the Mysteries of Looking and Feeling Young,” the updated edition of the bestselling book from Dr. Joseph Chang, chair of Nu Skin’s Scientific Advisory Board. The relaunch marks a significant milestone in the evolution of evidence-based beauty and wellness, bringing together decades of research that underpin Nu Skin’s science-led innovations — from ageLOC® technology to t...

ウィスコンシン州マディソン--(BUSINESS WIRE)--（ビジネスワイヤ） -- 中国国家薬品監督管理局（NMPA）は、中国において、OncoMate® マイクロサテライト不安定性（MSI）検出キットを第III類の体外診断用医療機器として承認しました。本製品は、メルク・アンド・カンパニー（米国ニュージャージー州ローウェイ）の抗PD-1抗体療法であるKEYTRUDA®（ペムブロリズマブ）治療の対象となる、MSI-High（MSI-H）の固形がん患者を特定するためのコンパニオン診断薬としての使用を目的としています。また、プロメガのコンパニオン診断薬として初めてNMPAの承認を取得しました。 「今回の承認は、中国における、より個別化された効果的ながん治療の実現に向けた一歩となります」と、プロメガのグローバル臨床マーケット・ディレクターであるアロク・シャルマは述べています。「当社は、革新的な技術や人命を救う効果的な治療法へのアクセス拡大につながる世界的なソリューションを提供するために、製薬企業と協業できることを誇りに思います。」 中国では、依然として世界でも特に高いがん負担に直面して...

MADISON, Wisconsin, USA--(BUSINESS WIRE)--Chinas nationale Aufsichtsbehörde für Medizinprodukte, NMPA (National Medical Products Administration), hat das OncoMate® -Kit zum Nachweis von Mikrosatelliteninstabilität (MSI) als In-vitro-Diagnostikum der Klasse III in China zugelassen. Das Kit soll als Begleitdiagnostikum zur Identifizierung von hochgradiger Mikrosatelliteninstabilität (MSI-H) bei Patienten mit soliden Tumoren für die Behandlung mit KEYTRUDA® (Pembrolizumab) dienen, einer Anti-PD-1-...

LOUISVILLE, Colo.--(BUSINESS WIRE)--Infleqtion, a global leader in quantum sensing and quantum computing powered by neutral-atom technology, today announced a successful live demonstration with Quantum Corridor showing how critical digital infrastructure can stay precisely synchronized without relying on GPS. Quantum Corridor is a quantum-safe, ultra-fast, and highly secure fiber-optic network in the Midwest enabling next-generation communication. The demonstration was conducted across 21.8 kil...

BOSTON--(BUSINESS WIRE)--Atrandi Biosciences announced it will present new scientific data and platform innovations at the SLAS2026 International Conference and Exhibition...

BEVERLY, Mass.--(BUSINESS WIRE)--HighRes® today announced a new brand identity and technology direction at SLAS2026, marking a pivotal evolution from building reliable automation platforms to delivering intelligent, accessible laboratory systems designed for the next era of scientific discovery. For more than two decades, HighRes has quietly powered some of the world’s most advanced laboratories, earning trust by delivering automation systems that work, last, and perform when failure is not an...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN), société pionnière de biotechnologie au stade clinique, spécialisée dans le développement de nouvelles thérapies pour restaurer, traiter et prévenir les troubles de la perte auditive, annonce aujourd'hui sa participation à la 49ème rencontre annuelle de l'Association pour la Recherche en Otorhinolaryngologie (ARO), qui se tiendra du 7 au 11 février 2026 à San Juan, Porto Rico. Arnaud Giese, Ph.D., Responsabl...